Gilles Della Corte, M.D., joined Relief in September 2020 as Chief Medical Officer. At Relief, Gilles is responsible for the clinical development of RLF-100™ in Europe, as well as interactions with and submissions to regulatory authorities. He brings over 40 years of professional experience, including 30 years in the biopharmaceutical industry. Gilles held several senior clinical research positions at several pharmaceutical and start-up companies, including Rhone-Poulenc-Rorer, Servier, Solvay Pharma, Serono, Anergis as well as CROs, including Phoenix Life Sciences, Larime, Omnicare Clinical Research, and Therapharm, where he was responsible for the development from proof of concept to life cycle management of projects in several disease areas, including cardiology, rheumatology, oncology, endocrinology and allergy. In 2016, Dr. Della Corte founded Dellmed Consulting, providing strategic advice and hands-on support for clinical development in various therapeutic areas, such as dermatology, oncology, parasitology, allergy, blood derivatives, and for CRO selection for companies ranging from biotech start-ups to well-established pharmaceutical companies.

Gilles holds an M.D. from Paris-Sud University (Paris XI) and is a Board-certified cardiologist with ten years of hospital practice.